Aegerion Pharma (NASDAQ: AEGR) reported Q1 EPS of ($1.72), $1.14 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $35.7 million versus the consensus estimate of $43 million.

Aegerion recorded $26.2 million in net product sales of JUXTAPID® (lomitapide) capsules in the first quarter of 2016, $23.6 million, or 90%, of which was from prescriptions written in the United States (U.S.). As of March 31, 2016, there were 498 active commercial patients on JUXTAPID therapy globally, approximately 373 of whom are U.S. patients.

GUIDANCE:

Aegerion Pharma sees FY2016 revenue of $130-150 million, versus the consensus of $174.9 million.

• Aegerion now expects full-year 2016 global net product sales of JUXTAPID to be between $90 million and $100 million, revised from the prior range of between $120 million and $140 million.
• Aegerion continues to expect full-year 2016 global net product sales of MYALEPT to be between $40 million and $50 million.
• Aegerion is currently analyzing all areas of investment and resources with a goal of reducing 2016 expenses, with the objective of returning to cash generation from operations in 2017.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.